# GDFATHER (NCT04725474)

> First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

No report yet. It can be ordered.

- Drugs tested: visugromab plus nivolumab; visugromab
- Indication: advanced-stage, relapsed/refractory solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04725474
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: CatalYm GmbH
- Conditions: Solid Tumor, Adult
- Interventions: visugromab (CTL-002); nivolumab
- Enrollment: 199
- Primary outcome: Adverse Events (Parts A & B)
- Primary outcome: Determination of DLT and MTD (Part A)
- Primary outcome: Evaluation of clinical efficacy according RECIST V1.1 (Part B)

## Indexed commentary on GDFATHER so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=gdfather-nct04725474
